- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03664830
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)
February 20, 2024 updated by: City of Hope Medical Center
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
The objective of this study is to investigate if up to two injections of plerixafor represent a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem progenitor cells (HSPC) for autologous hematopoietic cell transplantation (HCT) in sickle cell disease (SCD) patients
Study Overview
Detailed Description
Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for sickle cell disease (SCD) patients but its use is significantly limited by the lack of compatible donors.
Gene therapy using autologous hematopoietic stem cell (HSC) transplantation represents an alternative approach but requires the collection of significant numbers of cells.
Severe adverse events have been observed in SCD patients after mobilization using the standard agent granulocyte colony-stimulating factor (G-CSF), and bone marrow harvesting is also associated with side effects.
The use of a single administration of plerixafor has been suggested as an alternative mobilization strategy in SCD but may not mobilize sufficient number of HSC.
In this study, our primary objective is to assess if up to two injections of plerixafor (starting dose level: 240 µg/kg/dose) are safe in SCD patients and can recruit enough blood stem cells needed for future gene therapy.
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Joseph Rosenthal, MD
- Phone Number: 88442 626-256-4673
- Email: jrosenthal@coh.org
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Joseph Rosenthal, MD
- Phone Number: 88442 626-256-4673
- Email: jrosenthal@coh.org
-
Principal Investigator:
- Joseph Rosenthal, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Weight between 50 and 120 kg;
- Karnofsky performance status (KPS) ≥70%;
- Confirmed diagnosis of sickle cell disease with βS/βS or βS/β0 or βS/β+ genotype;
Must have had one or more of the following events in the 2 year period preceding enrollment:
- History of ≥2 severe vaso-occlusive pain crises (VOC) (or at least two episodes in the year preceding the setting up of regular transfusion protocol). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility.
- History of ≥1 episodes of acute chest syndrome despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea)
- Clinically significant neurological event (stroke) or any neurological deficit lasting 24 hours. A stroke is defined as a sudden neurological change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes.
- Prior treatment with regular RBC transfusion therapy, defined as receiving ≥8 transfusions per year for >1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
- Osteonecrosis of two or more joints;
- Anti-erythrocyte alloimmunization (>2 antibodies);
- Presence of sickle cell cardiomyopathy documented by Doppler echocardiography;
- Presence of any significant cerebral abnormality such as stenosis or occlusions on magnetic resonance imaging (MRA)
- Meet current eligibility requirements for donation for mobilization at the COH DAC;
- Adequate renal function: defined as a creatinine estimated FDR (eGFR) of ≥60 ml/min;
- Adequate liver function: defined by a serum conjugated (direct) bilirubin <2.5x upper limit of normal (ULN) for age; AST and ALT <5x ULN for age as per laboratory;
- Adequate cardiac function: defined as left ventricular ejection fraction >50%;
- Adequate hematologic parameters: WBC ≥2.5 x 10^9/L; platelet count ≥120 x10^9/L; hemoglobin >8 g/dL;
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry.
Exclusion Criteria:
- Diagnosed with alpha thalassemia (two or more gene deletions or any α-globin structural variants);
- Seropositivity for HIV-1/2 (Human Immunodeficiency Virus) or HTLV-1/2(Human T-Lymphotropic Virus);
- Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to treatment. Participants with fever should await resolution of symptoms before starting the treatment;
- Any clinically significant active infection which, in the opinion of the investigator, would require significant medical intervention;
- Abnormal pulmonary function tests (adults with mild or moderate obstruction or restriction or diffusion defects are eligible, per Investigator discretion).
- History of pulmonary hypertension, proven by cardiac catheterization;
- History of malignancy or immunodeficiency disorder, (i.e., subjects with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma or cutaneous squamous cell carcinoma;
- Participation in any study with an investigational agent or medical device within 90 days of screening;
- Major surgery in the past 30 days;
- Prior receipt of any gene transfer product;
- Bone marrow harvest in the past year;
- Known myelodysplasia of the bone marrow or abnormal bone marrow cytogenesis;
- Known hypersensitivity to plerixafor or any excipient contained in Mozobil;
- G-CSF or plerixafor medication within 4 weeks of treatment;
- Pregnant or nursing women;
- Any condition or chronic physical, neurological, or mental illness, which in the opinion of the investigator, makes participation ill advised.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Plerixafor
Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
|
Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicities
Time Frame: 120 hours (5 days) from the last injection of plerixafor
|
Scored using the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 4.03
|
120 hours (5 days) from the last injection of plerixafor
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stem cell mobilization feasibility
Time Frame: 6 hours after the first injection of plerixafor.
|
Assessed by measuring the number of mobilized CD34+ cells/µL of peripheral blood
|
6 hours after the first injection of plerixafor.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph Rosenthal, MD, City of Hope Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2018
Primary Completion (Estimated)
September 6, 2024
Study Completion (Estimated)
September 6, 2024
Study Registration Dates
First Submitted
September 7, 2018
First Submitted That Met QC Criteria
September 7, 2018
First Posted (Actual)
September 11, 2018
Study Record Updates
Last Update Posted (Estimated)
February 22, 2024
Last Update Submitted That Met QC Criteria
February 20, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17426
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Plerixafor
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
Stephen CoubanGenzyme, a Sanofi CompanyCompletedMalignant Lymphoma, Stem Cell TypeCanada
-
Kyowa Kirin Co., Ltd.CompletedMultiple Myeloma and Malignant LymphomaJapan
-
University of WashingtonCompleted
-
Genzyme, a Sanofi CompanySanofiCompletedNeuroblastoma | Brain Tumors | Ewing's Sarcoma/Soft Tissue SarcomaBelgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
-
University Hospital, Clermont-FerrandCompletedChildren Cancer, Solid TumorFrance
-
National Institute of Allergy and Infectious Diseases...Lombardi Comprehensive Cancer CenterTerminated
-
Genzyme, a Sanofi CompanyCompletedRenal ImpairmentUnited States
-
SanofiCompletedAutologous Haematopoietic Stem Cell TransplantChina